Borenius advised Nightingale Health Plc on its acquisition of Negen Oy

We advised Nightingale Health Plc (“Nightingale”) on its acquisition of Finnish genetic testing company Negen Ltd. (“Negen”). With this transaction, Nightingale acquires a core functionality in direct-to-consumer DNA testing, genomic data processing pipeline and polygenic risk algorithms for e.g. cardiovascular disease and type 2 diabetes. Combining Nightingale’s proprietary blood test with genomic data provides ground-breaking opportunities to improve early disease risk detection and accelerate preventative medicine.

Negen is a Finnish genetic testing and analysis technology company that was established in 2015. Negen provides its proprietary genetic tests directly to consumers and via its healthcare partners. Negen is an early-stage technology company that is in the very beginning phases of commercialisation. The company has, however, established partnerships with several private healthcare providers in Finland, which further validates the acquired technology.

The transaction is expected to be completed, subject to the fulfilment of the conditions precedent, in January 2022.